“…The anticontractile effect of PVAT was first described in rat thoracic aorta (Soltis and Cassis, 1991), followed by other vascular beds, including small mesenteric arteries (Aoqui et al, 2014;Gil-Ortega et al, 2014;Withers et al, 2017). It has been suggested that the presence of cardiometabolic risk factors, such as obesity, alters the secretory pattern of PVAT and might result in vascular dysfunction (Victorio and Davel, 2019). PVAT-dependent vascular dysfunction has been demonstrated in the aorta (da Costa et al, 2017;Ketonen et al, 2010) and mesenteric resistance arteries (Agabiti-Rosei et al, 2014;Gil-Ortega et al, 2014;Withers et al, 2017) in rat and mouse obese models.…”